Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis

Garcia-Manero, 2015, Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management, Am J Hematol, 90, 831, 10.1002/ajh.24102 Malcovati, 2013, Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet, Blood, 122, 2943, 10.1182/blood-2013-03-492884 Tefferi, 2009, Myelodysplastic syndromes, N Engl J Med, 361, 1872, 10.1056/NEJMra0902908 Shahrabi, 2016, Genetics and epigenetics of myelodysplastic syndromes and response to drug therapy: new insights, Oncol Rev, 10, 311, 10.4081/oncol.2016.311 Ganguly, 2016, Mutations of myelodysplastic syndromes (MDS): an update, Mutat Res Rev Mutat Res, 769, 47, 10.1016/j.mrrev.2016.04.009 Malcovati, 2015, SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts, Blood, 126, 233, 10.1182/blood-2015-03-633537 Donaires, 2016, Splicing factor SF3B1 mutations and ring sideroblasts in myelodysplastic syndromes: a Brazilian cohort screening study, Rev Bras Hematol Hemoter, 38, 320, 10.1016/j.bjhh.2016.06.002 Wahl, 2009, The spliceosome: design principles of a dynamic RNP machine, Cell, 136, 701, 10.1016/j.cell.2009.02.009 Bennett, 2016, Changes in the updated 2016 WHO classification of the myelodysplastic syndromes and related myeloid neoplasms, Clin Lymphoma Myeloma Leuk, 16, 607, 10.1016/j.clml.2016.08.005 Traina, 2014, Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms, Leukemia, 28, 78, 10.1038/leu.2013.269 Platzbecker, 2017, Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study, Lancet Oncol, 18, 1338, 10.1016/S1470-2045(17)30615-0 Malcovati, 2011, Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms, Blood, 118, 6239, 10.1182/blood-2011-09-377275 Malcovati, 2016, Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts, Br J Haematol, 174, 847, 10.1111/bjh.14215 List, 2006, Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion, N Engl J Med, 355, 1456, 10.1056/NEJMoa061292 Fenaux, 2011, A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1–risk myelodysplastic syndromes with del5q, Blood, 118, 3765, 10.1182/blood-2011-01-330126 Le Bras, 2011, Treatment by lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—the GFM experience, Leuk Res, 35, 1444, 10.1016/j.leukres.2011.05.034 Raza, 2008, Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q, Blood, 111, 86, 10.1182/blood-2007-01-068833 Komrokji, 2012, Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome, Blood, 120, 3419, 10.1182/blood-2012-03-415661 Thepot, 2016, A randomized phase II trial of azacitidine +/− epoetin-beta in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents, Haematologica, 101, 918, 10.3324/haematol.2015.140988